Wanbangde Pharmaceutical Holding Group Co Ltd (002082) — Net Asset Quality Index
Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has a Net Asset Quality Index of 59.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.55 Billion minus total liabilities of CN¥1.86 Billion yields net assets of CN¥2.70 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Wanbangde Pharmaceutical Holding Group C balance sheet liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Wanbangde Pharmaceutical Holding Group Co Ltd Net Asset Quality Index Over Time (2003–2025)
This chart shows how Wanbangde Pharmaceutical Holding Group Co Ltd's Net Asset Quality Index has evolved across 23 annual periods from 2003 to 2025. As of March 2026, the index stands at 59.2%, representing net assets of CN¥2.70 Billion against total assets of CN¥4.55 Billion CNY. For live market cap and overall valuation, see Wanbangde Pharmaceutical Holding Group C market capitalisation.
Annual Net Asset Quality Index for Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2025)
The table below presents the year-by-year Net Asset Quality Index for Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2025, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Wanbangde Pharmaceutical Holding Group C (002082) strategic asset index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 59.4% | CN¥2.61 Billion | CN¥4.39 Billion | CN¥1.78 Billion | ▼ -4.3 pp |
| 2024 | 63.7% | CN¥2.76 Billion | CN¥4.33 Billion | CN¥1.57 Billion | ▼ -0.5 pp |
| 2023 | 64.2% | CN¥2.76 Billion | CN¥4.30 Billion | CN¥1.54 Billion | ▼ -2.7 pp |
| 2022 | 66.9% | CN¥2.82 Billion | CN¥4.22 Billion | CN¥1.40 Billion | ▲ +4.1 pp |
| 2021 | 62.8% | CN¥2.74 Billion | CN¥4.37 Billion | CN¥1.63 Billion | ▲ +12.3 pp |
| 2020 | 50.5% | CN¥2.86 Billion | CN¥5.66 Billion | CN¥2.80 Billion | ▲ +0.2 pp |
| 2019 | 50.3% | CN¥1.91 Billion | CN¥3.80 Billion | CN¥1.89 Billion | ▼ -10.3 pp |
| 2018 | 60.6% | CN¥1.72 Billion | CN¥2.85 Billion | CN¥1.12 Billion | ▼ -15.8 pp |
| 2017 | 76.4% | CN¥1.60 Billion | CN¥2.10 Billion | CN¥496.58 Million | ▼ -7.9 pp |
| 2016 | 84.2% | CN¥1.40 Billion | CN¥1.66 Billion | CN¥261.85 Million | ▲ +0.9 pp |
| 2015 | 83.3% | CN¥1.35 Billion | CN¥1.62 Billion | CN¥270.28 Million | ▼ -0.3 pp |
| 2014 | 83.6% | CN¥1.30 Billion | CN¥1.55 Billion | CN¥254.69 Million | ▲ +6.9 pp |
| 2013 | 76.7% | CN¥1.19 Billion | CN¥1.55 Billion | CN¥361.07 Million | ▲ +6.6 pp |
| 2012 | 70.1% | CN¥1.10 Billion | CN¥1.57 Billion | CN¥469.09 Million | ▼ -2.8 pp |
| 2011 | 72.9% | CN¥1.05 Billion | CN¥1.45 Billion | CN¥392.22 Million | ▲ +1.8 pp |
| 2010 | 71.1% | CN¥936.13 Million | CN¥1.32 Billion | CN¥380.46 Million | ▼ -1.4 pp |
| 2009 | 72.5% | CN¥811.59 Million | CN¥1.12 Billion | CN¥307.39 Million | ▲ +2.8 pp |
| 2008 | 69.7% | CN¥712.31 Million | CN¥1.02 Billion | CN¥309.46 Million | ▲ +25.0 pp |
| 2007 | 44.8% | CN¥415.12 Million | CN¥927.63 Million | CN¥512.51 Million | ▲ +2.7 pp |
| 2006 | 42.0% | CN¥357.72 Million | CN¥851.57 Million | CN¥493.85 Million | ▲ +18.9 pp |
| 2005 | 23.1% | CN¥152.88 Million | CN¥661.73 Million | CN¥508.84 Million | ▼ -9.6 pp |
| 2004 | 32.7% | CN¥136.17 Million | CN¥416.66 Million | CN¥280.48 Million | ▼ -5.0 pp |
| 2003 | 37.7% | CN¥98.53 Million | CN¥261.57 Million | CN¥163.05 Million | — |